Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Go online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy. Upon completion of this activity, participants should be better able to: Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM); Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM; and Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting.